AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9488498
Drug: Histamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine infusion (0.16 microg/kg/min) after 30 minutes of pretreatment with low L-NMMA
Trial: 9488498
Drug: Histamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine infusion (0.16 microg/kg/min) after 30 minutes of pretreatment with high L-NMMA
Trial: 9488498
Drug: Histamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine infusion alone (no L-NMMA pretreatment)
Trial: 3386328
Drug: Flunitrazepam (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (three intravenous dose levels)
Trial: 9075669
Drug: Spironolactone 225
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone 225 mg/day
Trial: 8416267
Drug: Low-dose isotretinoin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isotretinoin (0.5 mg per kilogram per day)
Trial: 8416267
Drug: Beta carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta carotene (30 mg per day)
Trial: 30796508
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg phytosomal curcumin (Curserin®: 200 mg curcumin, 120 mg phosphatidylserine, 480 mg phosphatidylcholine and 8 mg piperine from Piper nigrum L. dry extract) for 8 weeks
Trial: 30796508
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg phytosomal curcumin (Curserin®)
Trial: 29406428
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) for 24 weeks
Trial: 29406428
Drug: Isoniazid preventive
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid preventive therapy (IPT) and antiretroviral therapy (ART)
Trial: 26523653
Drug: Telmisartan (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (160 mg daily for 3 weeks)
Trial: 20142024
Drug: Baseline NT-proBNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline NT-proBNP levels measured in pg/mL using the Elecsys proBNP assay (Roche)
Trial: 15659491
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg oral gefitinib daily continuously
Trial: 15659491
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral gefitinib daily continuously
Trial: 12516646
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading of machined-surface Brånemark implants in healed bone
Trial: 12516646
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading of machined-surface Brånemark implants in fresh extraction sites
Trial: 12516646
Drug: Functional loading
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional loading of implants
Trial: 8556789
Drug: Artemether (Art)
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether (Art) 6 mg/kg followed by repeated dosing every 15 days for 3 times.
Trial: 2399780
Drug: Labetalol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (0.25 mg/kg in divided doses, followed by 0.50 mg/kg until blood pressure < 160/90 mmHg or total dose of 300 mg)
Trial: 2399780
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (infusion starting at 0.5 micrograms/kg/min, titrated up to 6.0 micrograms/kg/min)
Trial: 31577104
Drug: Antioxidant supplement
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplement treatment
Trial: 28375803
Drug: First-generation cephalosporin
RxNorm normalized name: First-generation cephalosporins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation cephalosporin (cefazolin; 1 g) (Group 2, n=191)
Trial: 28375803
Drug: Second-generation cephalosporin
RxNorm normalized name: Second-generation cephalosporins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation cephalosporin (cefuroksim aksetil; 750 mg) (Group 3, n=186)
Trial: 21221990
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (CC) - subjects refrained from strenuous exercise for 2 days prior to IET.
Trial: 21221990
Drug: Resistance exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance exercise condition (REC) and Control condition (CC)
Trial: 28374496
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg
Trial: 12090591
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg of leuprorelin acetate depot for 8 weeks
Trial: 1932607
Drug: Ansaid (film‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ansaid (film‐coated 100 mg tablet)
Trial: 1932607
Drug: Froben (sugar‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Froben (sugar‐coated 100 mg tablet)
Trial: 28705885
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of fibroblast growth factor 23 to a model of annualized decline in eGFR≥3.0 ml/min per 1.73 m²
Trial: 26562604
Drug: 40 mg/dl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/dl (low)
Trial: 26562604
Drug: 65 mg/dl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 65 mg/dl (moderate)
Trial: 26562604
Drug: 0 mg/dl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/dl (placebo)
Trial: 19143752
Drug: Topical pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pimecrolimus cream 1% (n = 35)
Trial: 19143752
Drug: Betamethasone cream
RxNorm normalized name: Betamethasone Cream
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone cream 0.1% (n = 35)
Trial: 17500625
Drug: Original treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original treatment condition
Trial: 15024982
Drug: Vaxigrip vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaxigrip vaccine combined with Pneumo 23 and Avaxim vaccines
Trial: 15024982
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not specified, but implied as those not receiving the combined vaccines)
Trial: 12180720
Drug: etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 90 mg once daily
Trial: 9834800
Drug: Mivacurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.15 mg.kg‐1 (MIV 15)
Trial: 9834800
Drug: Mivacurium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.25 mg.kg‐1 (MIV 25)
Trial: 9834800
Drug: Atracurium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.3 mg.kg‐1 (ATR 30)
Trial: 9834800
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg.kg‐1 (ATR 50)
Trial: 9834800
Drug: Vecuronium 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.06 mg.kg‐1 (VEC 06)
Trial: 9834800
Drug: Vecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.1 mg.kg‐1 (VEC 10)
Trial: 7626850
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 and Cyclophosphamide 1200 mg/m2
Trial: 7626850
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 and Cyclophosphamide 900 mg/m2
Trial: 2748870
Drug: Apomorphine (Apo)
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apomorphine (Apo) HCl 0.25, 0.5, 0.75, and 1.0 mg sc
Trial: 2253535
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg twice a day
Trial: 23690338
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin
Trial: 31426703
Drug: Interarytenoid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interarytenoid injection augmentation
Trial: 28202370
Drug: Intramedullary nailing
RxNorm normalized name: FUNGI NAIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramedullary nailing & PRP injection/gel application (study group A)
Trial: 28202370
Drug: Closed intramedullary
RxNorm normalized name: atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Closed intramedullary nailing & PRP injection (subgroup A1)
Trial: 28202370
Drug: Open intramedullary
RxNorm normalized name: atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open intramedullary nailing & PRP gel with fibrin membrane (subgroup A2)
Trial: 26096484
Drug: Epidural injections
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injections of corticosteroids with lidocaine
Trial: 21970138
Drug: Paravertebral block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral block (PVB) with 0.2 ml/kg levobupivacaine
Trial: 21970138
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block (CB) with 1 ml/kg levobupivacaine
Trial: 16400054
Drug: Phenylalanine intake
RxNorm normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylalanine intake of 48 mg x kg(‐1) x d(‐1)
Trial: 16400054
Drug: Graded intakes
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded intakes of phenylalanine (5, 10, 15, 25, 35, 45, 60, and 70 mg x kg(‐1) x d(‐1))
Trial: 11284803
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg levocetirizine
Trial: 21874559
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg cetirizine
Trial: 11284803
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg dextrocetirizine
Trial: 9815721
Drug: LSF, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSF, 1.5 mg/kg i.v. bolus every 6 h during IL-2 therapy
Trial: 9815721
Drug: Placebo every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every 6 h during IL-2 therapy
Trial: 3680816
Drug: Uniphyl (once-a-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyl (once-a-day theophylline formulation) after breakfast
Trial: 3680816
Drug: Uniphyl (once-a-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyl (once-a-day theophylline formulation) after overnight fast
Trial: 3680816
Drug: Reference theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference theophylline solution
Trial: 27478057
Drug: Web-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based therapy tools and increased team meetings
Trial: 19050530
Drug: Preoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous dosing of cefazolin
Trial: 19050530
Drug: Intraoperative dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative dosing by irrigation of cefazolin
Trial: 16631656
Drug: Off-pump (beating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off-pump (beating heart) and heparin 3 mg/kg (n = 20)
Trial: 16631656
Drug: Off-pump (beating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off-pump (beating heart) and heparin 1 mg/kg (n = 20)
Trial: 9696209
Drug: Serum IgG
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum IgG antibodies to C. trachomatis in poor responders (44.7%)
Trial: 10150262
Drug: Ampicillin/sulbactam (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin/sulbactam (1.0 to 2.0 g ampicillin plus 0.5 to 1.0 g sulbactam every 6 hours)
Trial: 10150262
Drug: Cefoxitin (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (1.0 to 2.0 g every 6 hours)
Trial: 3190058
Drug: Zidovudine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (2 g/d for 2 weeks, and 1 g/d for 6 weeks)
Trial: 31099167
Drug: Waiting-list group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list group maintaining daily routines
Trial: 23752604
Drug: G-CSF therapy
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF therapy and CVC-related sepsis
Trial: 16922471
Drug: Pre-treatment levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment levels
Trial: 21765206
Drug: Alprazolam (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (low and high doses)
Trial: 16648504
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan 1.7 mg/m2/d x 5 with IV cisplatin 60 mg/m2 on day 5 (TC)
Trial: 16648504
Drug: Intravenous etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous etoposide 100 mg/m2/d x 3 with IV cisplatin 80 mg/m2 on day 1 (PE)
Trial: 30807294
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy
Trial: 30848868
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily short-message-based re-education (SMRE)
Trial: 30848868
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (oral and written instructions)
Trial: 16198059
Drug: risperidone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: risperidone (4 mg/day)
Trial: 15349006
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg for 8 weeks
Trial: 11286468
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/day, n = 84)
Trial: 11286468
Drug: Toremifene (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (40 mg/day, n = 83)
Trial: 9200375
Drug: Newborns (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newborns (mean leptin concentration 10.57 ng/mL)
Trial: 9200375
Drug: Children in
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children in Tanner stages 1 and 2 (mean leptin concentration 3.04 ng/mL)
Trial: 9200375
Drug: Mothers (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mothers (mean leptin concentration 28.8 ng/mL)
Trial: 7905185
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Roxatidine acetate once daily, late in the evening (between 10.00 p.m. and 11.00 p.m.)
Trial: 7905185
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg Roxatidine acetate once daily, early in the evening (between 6.00 p.m. and 7.00 p.m.)
Trial: 7905185
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (bedtime and early evening administration)
Trial: 17371783
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 mg daily)
Trial: 2952436
Drug: Bendrofluazide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide (2.5 mg daily)
Trial: 26577062
Drug: Mirtazapine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (single dose)
Trial: 23864536
Drug: No-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment control (n = 68)
Trial: 19897276
Drug: Choline supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline supplement (1500 mg twice daily)
Trial: 20137476
Drug: Low-dose amiodarone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose amiodarone
Trial: 2977272
Drug: Zoladex (LH-RH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoladex (LH-RH analogue), administered every 28 days
Trial: 29346524
Drug: Multidisciplinary intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidisciplinary intervention (exercise training, hyperproteic nutritional shakes, memory training, medication review)
Trial: 12358242
Drug: Parenteral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral feeding (group TPN), n = 27
Trial: 7059489
Drug: Sherry (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sherry (40 ml) after placebo
Trial: 31157682
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ROTEM values with protein C or antithrombin
Trial: 25715353
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate and high-dose prednisolone (tapering for 2 weeks)
Trial: 22982689
Drug: Pharmacist-initiated reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-initiated reduction of ADS score after multidisciplinary drug reviews
Trial: 19554274
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of connective tissue massage, Mc Mennell joint manipulation, and home exercise programme
Trial: 15054673
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg IV ondansetron before anesthetic induction plus 4 mg IV immediately before extubation (experimental group)
Trial: 15054673
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg IV ondansetron before anesthetic induction (control group)
Trial: 11642472
Drug: Methylphenidate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (10 mg and 20 mg)
Trial: 7872224
Drug: 3.9 g
RxNorm normalized name: aspirin 3.9 GM Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.9 g konjac glucomannan daily for 4 weeks
Trial: 28673312
Drug: Reduced nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced nicotine content (RNC) cigarettes (11.6 to 0.2 mg/cigarette)
Trial: 28673312
Drug: Usual nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual nicotine content (UNC) cigarettes (11.6 mg/cigarette)
Trial: 18266532
Drug: Structural ecosystems
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structural ecosystems therapy (SET)
Trial: 16780497
Drug: Topical photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical photodynamic therapy (PDT) weekly for 4 weeks
Trial: 16780497
Drug: Topical paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical paromomycin twice-daily for 4 weeks
Trial: 11000341
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg daily plus calcium supplementation 500 mg daily
Trial: 11000341
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus calcium supplementation 500 mg daily
Trial: 1377290
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination (DRE) followed by serum PSA determination
Trial: 30451595
Drug: EFV/FTC/TDF therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV/FTC/TDF therapy
Trial: 29632533
Drug: M72/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M72/AS01 vaccine
Trial: 19233181
Drug: High-dose celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose celecoxib (400 mg twice daily)
Trial: 19233181
Drug: Low-dose celecoxib
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose celecoxib (200 mg twice daily)
Trial: 19706349
Drug: Fentanyl HCl
RxNorm normalized name: fentanyl HCl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl HCl iontophoretic transdermal system (ITS)
Trial: 17505380
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of morphine provided by an intravenous patient-controlled analgesia (IV PCA) pump
Trial: 15040557
Drug: CV8 (dihydroartemisinin/piperaquine/trimethoprim/primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CV8 (dihydroartemisinin/piperaquine/trimethoprim/primaquine 256/2560/720/40 mg)